We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BELLUS Health Inc | TSX:BLU | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 19.48 | 19.46 | 19.52 | 0 | 01:00:00 |
From May 2019 to May 2024
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.
Conference Presentation Details:
Event: UBS 2019 Global Healthcare Conference
Date/Time: Monday, May 20, 2019 at 3:30 p.m. EDT
Location: New York, NY
Event: Jefferies 2019 Healthcare Conference
Date/Time: Wednesday, June 5, 2019 at 3:30 p.m. EDT
Location: New York, NY
Event: Raymond James Life Sciences and MedTech Conference
Date/Time: Wednesday, June 19, 2019 at 8:35 a.m. EDT
Location: New York, NY
Live webcasts from the UBS, Jefferies and Raymond James conference presentations may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead product candidate, BLU-5937, is being developed for the treatment of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. In addition to chronic cough, BLU-5937 may potentially have clinical benefit in other afferent hypersensitization-related disorders, such as visceral pain, hypertension, and migraine, among others. BELLUS Health is currently conducting pre-clinical studies in additional undisclosed indications.
Chronic cough is classified as a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality-of-life. More than 26 million adults in the United States suffer from chronic cough. Of these patients, more than 2.6 million have unexplained or refractory chronic cough lasting for more than a year. There are currently no approved treatments for refractory chronic cough, creating a significant unmet medical need.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005163/en/
Investors:BELLUS HealthFrançois DesjardinsVice-President, Finance450-680-4525fdesjardins@bellushealth.com
Solebury TroutChad Rubin646-378-2947crubin@soleburytrout.com
Media:Solebury TroutBrad Miles646-513-3125bmiles@soleburytrout.com
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
